Log In
BCIQ
Print this Print this
 

IMA942

  Manage Alerts
Collapse Summary General Information
Company immatics biotechnologies GmbH
DescriptionNot disclosed
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationGastric cancer
Indication DetailsTreat gastric cancer
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$17.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/18/2013

Undisclosed

$17.0M

$1,000.0M

Get a free BioCentury trial today